Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

The latest trading session saw AbbVie (ABBV) ending at $193.45, denoting a -1.16% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.03%. At the same time, the Dow ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and uncertain ...

The Food and Drug Administration recently intervened regarding a migraine medication ad featuring tennis superstar Serena ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.